The Claim
GLP-1 receptor antagonism with exendin(9-39) reverses liraglutide-induced improvements in insulin sensitivity and increases postprandial glucose and glucagon levels in individuals with obesity and prediabetes.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Blocking GLP-1 receptors with exendin(9-39) eliminates the improvement in insulin sensitivity caused by liraglutide and raises blood glucose and glucagon levels after meals in people with obesity and prediabetes.
See the scientific wording
GLP-1 receptor antagonism with exendin(9-39) reverses liraglutide-induced improvements in insulin sensitivity and increases postprandial glucose and glucagon levels in individuals with obesity and prediabetes, confirming that these metabolic effects are dependent on continuous GLP-1 receptor activation.
When GLP-1 binds to its receptor, it tells the pancreas to stop releasing glucagon and makes the liver and muscles more responsive to insulin. This lowers blood sugar after meals. If the receptor is blocked, glucagon rises, insulin sensitivity drops, and blood sugar spikes.
What the research says
1 studyWhen scientists blocked the GLP-1 receptor in people taking liraglutide, their blood sugar went up and their body’s ability to use insulin got worse — proving that liraglutide only works if the receptor stays active.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.